|Dr. Anil R. Diwan||Chairman, Pres, Acting CEO & Sec.||447.92k||N/A||1959|
|Ms. Meeta R. Vyas SB, MBA||Chief Financial Officer||129.6k||N/A||1959|
|Dr. Eugene Seymour||Chief Exec. Officer Emeritus||447.92k||N/A||1941|
|Dr. Randall W. Barton Ph.D.||Chief Scientific Officer & Chief Regulatory Officer||N/A||N/A||1947|
|Dr. Jayant Tatake Ph.D.||VP of R&D||N/A||N/A||N/A|
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
NanoViricides, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.